在炎症性肠道疾病中对阿达利穆马布生物类似药物切换计划的单中心分析
Louise Rabbitt1, Áine Keogh2, Linda Duane2
1Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway, Ireland.
British journal of clinical pharmacology
|April 30, 2025
概括
转换为生物类似的阿达利穆马布 (Amgevita) 维持了炎症性肠病患者的疾病控制和生活质量. 健康焦虑影响了副作用报告,但实现了显著的成本节省.
科学领域:
- 药物经济学 药物经济学
- 胃肠病学 胃肠病学
- 生物类似疗法生物类似疗法
背景情况:
- 生物类似的阿达利穆马布 (Amgevita) 是Humira的经济有效的替代品.
- 切换到生物类药物可能会触发nocebo效应,影响患者的结果.
- 在评估生物相似转变时,了解心理社会因素至关重要.
研究的目的:
- 评估从阿达利穆马布 (Humira) 转换为生物类似阿达利穆马布 (Amgevita) 的患者的临床和经济结果.
- 研究心理社会变量 (如健康焦虑) 对患者转换后体验的影响.
- 评估非医疗转换为生物类似的阿达利姆巴对炎症性肠病 (IBD) 管理的影响.
主要方法:
- 一项前性队列研究,涉及64名患有炎症性肠病 (IBD) 的患者.
- 通过哈维-布拉德肖指数/部分梅奥得分,便calprotectin和C反应蛋白评估的客观疾病活性.
- 用IBD控制问卷 (IBDCQ) 测量的主观症状负担;使用健康焦虑指数 (HAI) 评估健康焦虑.
主要成果:
- 在切换后,客观疾病活动或炎症标志物没有显著变化.
- 在IBD控制问卷分数的边际改善 (P=.043).
- 在较高的健康焦虑指数得分和报告不良事件的几率增加之间发现了显著的关联 (P=.0079).
结论:
- 转换为Amgevita并没有对IBD患者的疾病控制或生活质量产生负面影响.
- 健康焦虑是继生物类似药阿达利穆马布切换后报告不良事件的重要预测因素.
- 实现了大量的成本节约,突出了生物类似药采用带来的经济效益.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
100
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
100
Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
223
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
223


